Nuclea Biotechnologies Receives U.S. Patent 8,129,125 B2 for EGFR Inhibitor Assay

March 7, 2012

Pittsfield, MA -- Biomarker pioneer Nuclea Biotechnologies, Inc. today announced the United States Patent and Trademark Office has issued patent number 8,129,125 B2 covering a gene/protein signature for predicting the therapeutic efficacy of EGFR inhibitors in lung cancer patients. 

The invention relates to a method for determining if a patient afflicted with lung cancer is likely to respond to treatment with a therapeutic agent that inhibits EGFR, such as gefitinib (IRESSA®) or erlotinib (TARCEVA®).  Lung cancer is a condition where early detection and early effective treatment are keys to survival. Nuclea’s method provides clinicians with a valuable tool for determining and monitoring the efficacy of treatment with an EGFR inhibitor, and benefits lung cancer patients by identifying the subpopulation of patients that would derive the most benefit from these agents, as well as those patients that would benefit from a different therapeutic treatment.

This is the tenth patent for Nuclea, which discovers and develops biomarkers and diagnostic assays that can help predict the stage or aggressiveness of certain cancers, as well as which treatments will be effective for certain patients, depending on their genetic makeup.

“This is another major step forward for Nuclea and the future of personalized medicine,” said Patrick J. Muraca, president & CEO of Nuclea Biotechnologies, Inc.  “Our continued research in this field will lead to more comprehensive detection and more effective treatment of lung cancer and other deadly diseases.”

Nuclea Biotechnologies, Inc. is headquartered in Pittsfield, Massachusetts. Nuclea has three lines of business, each of which is operated by a separate wholly-owned subsidiary: Nuclea Diagnostic Laboratories (“NDL”) which has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer; Nuclea Biomarkers (“NBM”) which performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries and performs services by analyzing and testing the efficacy and validating other indications of existing therapeutics utilizing a highly characterized and consented patient database; and Nuclea Biotherapeutics (“NBT”) which develops novel therapeutics.

 

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.